Cas:6882-28-6 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline manufacturer & supplier

Chemical Name:7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline

CAS.NO:6882-28-6

Synonyms:3,4-dihydro-6,7-(methylenedioxy)-isoquinoline;1,3-Dioxolo[4,5-g]isoquinoline,7,8-dihydro;6,7-methylenedioxy-3,4-dihydroisoquinoline (norhydrastinine);6,7-methylenedioxy-3,4-dihydro-2H-isoquinoline;6,7-(methylenedioxy)-3,4-dihydroisoquinoline;methylenedioxy-3,4-dihydroisoquinoline

Molecular Formula:C₁₀H₉NO₂

Molecular Weight:175.18400

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:30.82000

Exact Mass:175.06300

LogP:0.82590

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,4-dihydro-6,7-(methylenedioxy)-isoquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methylenedioxy-3,4-dihydroisoquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methylenedioxy-3,4-dihydroisoquinoline Use and application,6,7-(methylenedioxy)-3,4-dihydroisoquinoline technical grade,usp/ep/jp grade.

Related News: Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline manufacturer A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline vendor Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline factory At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content.